AMX0035 and Progressive Supranuclear Palsy
Brief description of study
Study A35-009 is a two-phase study to evaluate the efficacy and safety of AMX0035 in participants with PSP, consisting of a randomized, double-blind, placebo-controlled phase followed by an optional open-label extension (OLE) phase. The double-blind phase of the study consists of a Screening Period of up to 6 weeks, a 52-week Treatment Period, and a remote Safety Follow-up Visit occurring 4 weeks (+ 7 days) after the End of Treatment Visit. The OLE Treatment Period will be up to 52 weeks.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
